Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prostatype Genomics ABOSTO:PROGEN +23.32%23 3-Year EBITDA Growth Rate is 85.20% as of Dec. 2025, which is 2% above its 10-year median of 83.70. GuruFocus rates OSTO:PROGEN with a GF Score™ of 23/100 and a GF Value™ of kr0.04 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 166 Medical Diagnostics & Research companies, Prostatype Genomics AB ranks better than 97.59% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 85.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 76.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Prostatype Genomics AB was 93.80% per year. The lowest was -92.40% per year. And the median was 83.70% per year.
Prostatype Genomics AB (OSTO:PROGEN) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Prostatype Genomics AB 3-Year EBITDA Growth Rate Related Terms
OSTO:PROGEN vs TMO, DHR, IDXX: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, Prostatype Genomics AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prostatype Genomics AB 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Prostatype Genomics AB's 3-Year EBITDA Growth Rate falls into.
Prostatype Genomics AB 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 85.20% mean?
Prostatype Genomics AB (OSTO:PROGEN) has a 3-Year EBITDA Growth Rate of 85.20% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Prostatype Genomics AB and its competitors. This is near median its historical median of 83.70. According to the industry distribution chart, Prostatype Genomics AB ranks #4 out of 166 companies in the Medical Diagnostics & Research industry, placing it in the top 2.4%.
Is Prostatype Genomics AB's 3-Year EBITDA Growth Rate too high?
Prostatype Genomics AB's current 3-Year EBITDA Growth Rate of 85.20% is near median its 10-year median of 83.70. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 10.80. Prostatype Genomics AB's value of 85.20% is 688.9% above this industry median. Based on the distribution chart, Prostatype Genomics AB ranks #4 out of 166 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Prostatype Genomics AB has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's 3-Year EBITDA Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Prostatype Genomics AB ranks #4 out of 166 companies for 3-Year EBITDA Growth Rate. This places Prostatype Genomics AB in the top 2% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 10.80. Prostatype Genomics AB's value of 85.20% is 688.9% above this benchmark. While the company's 10-year median is 83.70 vs. the industry median of 10.80, Prostatype Genomics AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 10.80, based on 166 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prostatype Genomics AB's current 3-Year EBITDA Growth Rate of 85.20% is 688.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Prostatype Genomics AB and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 10.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prostatype Genomics AB's current 3-Year EBITDA Growth Rate is 85.20%, which is near median its own 10-year median of 83.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.04, compared to a current price of kr0.16 — trading 290% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 85.20%, which is near median its 10-year median of 83.70 and 688.9% above the Medical Diagnostics & Research industry median of 10.80. Prostatype Genomics AB's overall GF Score™ is 23/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current 3-Year EBITDA Growth Rate is 85.20% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued.
The current stock price of kr0.16 is trading 290% above its estimated GF Value™ of kr0.04.
GuruFocus considers Prostatype Genomics AB to be Significantly Overvalued.
Key valuation signals for OSTO:PROGEN:
3-Year EBITDA Growth Rate: 85.20% (near median its 10-year median of 83.70)
GF Value™: kr0.04 vs. price of kr0.16 (290% above fair value)
Industry Position: 688.9% above the Medical Diagnostics & Research median (#4 of 166)
No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
23GF Score
Get the complete analysis for OSTO:PROGEN
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:PROGEN has been successfully added to your 
